bioAffinity Technologies, Inc. BIAF 深 滬
等待開盤 01-29 09:30:00 美东时间
1.26
-0.060
-4.55%
華盛通- 最 高1.33
- 今 開1.28
- 成交量 4.51万股
- 最 低 1.254
- 昨 收 1.32
- 總市值 124.19万
- 52周最高 46.53
- 市盈率 靜 --
- 換手率 4.57%
- 52周最低 1.1101
- 委 比 -52.38%
- 總股本 98.56万
- 歷史最高 466.50
- 量 比 0.91
- 振 幅 5.76%
- 歷史最低 1.17
- 每 手 1
- 風險率 6.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioAffinity Technologies Chief Medical Officer To Present Data At American Cancer Society National Lung Cancer Roundtable On CyPath Lung Cytometry Test
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer Gordon Downie, MD, PhD,
2025-12-03 21:08
bioAffinity Technologies Q3 EPS $(4.74) Misses $(2.70) Estimate, Sales $1.446M Beat $1.411M Estimate
bioAffinity Technologies (NASDAQ:BIAF) reported quarterly losses of $(4.74) per share which missed the analyst consensus estimate of $(2.70) by 75.56 percent. This is a 1.25 percent increase over losses of $(4.80) per
2025-11-14 21:13
bioAffinity Technologies Reports Continued Sales Growth For Its Noninvasive Lung Cancer Test, CyPath Lung, With Test Volumes More Than Doubling Since The Start Of 2025
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced continued sales growth of its noninvasive lung
2025-11-05 21:08
bioAffinity Technologies shares are trading higher after the company announced the Australian Patent Office accepted its patent application for a platform to detect and characterize multiple lung diseases.
bioAffinity Technologies shares are trading higher after the company announced ...
2025-10-28 20:07
bioAffinity Technologies Presents at CHEST 2025 Conference
bioAffinity Technologies, Inc. ( ($BIAF) ) has provided an announcement. On Oct...
2025-10-21 06:18
BioAffinity Technologies Gets Notification Of Allowance From United States Patent and Trademark Office For New Patent Covering AI-Built Algorithm, Flow Cytometry Platform To Detect Lung Cancer
SAN ANTONIO, Texas--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially
2025-10-16 20:09
bioAffinity Regains Nasdaq Compliance, Ensures Continued Trading
bioAffinity Technologies, Inc. ( ($BIAF) ) has issued an update. On October 15,...
2025-10-15 21:49
bioAffinity Technologies launches $1.8M direct financing
bioAffinity Technologies (NASDAQ:BIAF) has entered into definitive agreements for the purchase and sale of 720,000 shares of common stock, par value $0.007 per share, at a purchase price of $2.50 per...
2025-10-09 04:31
bioAffinity Technologies Reports Sales Of Its CyPath Lung Diagnostic Test For Lung Cancer Hit Record High In Q3 2025, Marking 95% Increase Over The Previous Quarter
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced sales of its CyPath® Lung diagnostic test for
2025-10-07 20:08
bioAffinity Technologies Completes $4.8M Stock Offering
The latest update is out from bioAffinity Technologies, Inc. ( ($BIAF) ). On Se...
2025-10-01 05:29
